Securities Fraud Investigation Into 3D Systems Corporation (DDD) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) investors concerning the Company's possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON 3D SYSTEMS CORPORATION (DDD), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On March 26, 2025, 3D Systems released its fourth quarter and full year 2024 financial results, missing consensus estimates in non-GAAP earnings-per-share and sales revenue, citing 'lowers hardware systems sales due to macroeconomic factors that are negatively impacting demand.' The Company also reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program." The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing . . . which led to refinement of the milestone technical criteria."
On this news, 3D Systems' stock price fell $0.57, or 21%, to close at $2.15 per share on March 27, 2025, thereby injuring investors.
Then, on May 12, 2025, after market hours, 3D Systems released its first quarter 2025 financial results, missing consensus estimates due, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. The Company further disclosed that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty.
On this news, 3D Systems' stock price fell $0.68, or 26.6%, to close at $1.87 per share on May 13, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding 3D Systems should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
New York Post
an hour ago
- New York Post
Ousted Dem ‘super mayor' charges whopping price tag for tell-all book while dodging legal troubles
The embattled former Chicago suburb 'super mayor' has announced her latest business venture as her legal woes continue to pile up following a tumultuous time in office. Tiffany Henyard, the former Democratic mayor of Dolton, has announced she is peddling a 'tell-all' autobiography, titled 'Standing on Business.' In a Facebook post, the disgraced politician vowed 'the real story is coming' while sharing a link to pre-order the book – which boasts a price tag of $99 and is reportedly the first of a three-part series – from a self-publishing website. 'From mommy moves to making history, [Henyard] is not just showing up,' she wrote. 'She's standing on business.' However, the former mayor's constituents appeared less than pleased, taking their opinions online to voice their skepticism of Henyard's latest business venture. 'Still trying to hustle money!' one commenter said in the Dolton Politics Facebook Page. 'Michelle Obama's bestseller was cheaper than this mess,' another poster wrote. 'The unmitigated gal!' Henyard's attorneys did not immediately respond to Fox News Digital's request for comment. Henyard's announcement comes as she faces several legal woes stemming from her time as Dolton mayor and Thornton Township supervisor after her reelection bid proved unsuccessful. 3 Former Dolton mayor Tiffany Henyard announced on Facebook that she is writing an autobiography titled, 'Standing on Business.' FOX News Earlier this month, Henyard pleaded the Fifth in a court hearing over a Freedom of Information Act lawsuit from her time at the helm. 'The smear campaign against Tiffany Henyard, which began while she was in office, continues even now that she is out of office,' her attorney, Beau Bridley, previously said in a statement to Fox News Digital. Henyard was previously held in contempt of court after she failed to hand over public documents related to the lawsuit. 3 Henyard received controversy on social media from her former constituents amid her ongoing legal issues. FOX News Her attorney subsequently acknowledged the former mayor does not have the requested documents, with an Illinois judge ruling Henyard's legal team can submit an affidavit in its place. 'The mayor has no document that the plaintiff seeks,' Bridley said. 'This matter is going to be resolved with a simple affidavit. The whole hearing was much ado about nothing.' 3 The Dolton Politics Facebook page received comments such as one saying, 'Still trying to hustle money!' with another commenter replying, 'The unmitigated gal!' FOX News The lawsuit was initially filed by the Edgar County Watchdogs Inc. in response to the organization suing Henyard and the Village of Dolton for failing to produce financial records after the documents were requested under federal FOIA laws. 'We had little doubt Ms. Henyard would use losing the election as an excuse not to produce the documents,' Edward 'Coach' Weinhaus, attorney for Edgar County Watchdogs, previously said in a statement to Fox News Digital. 'Invoking the Fifth Amendment for a criminal investigation was an added wrinkle. The Watchdogs will keep looking for the documents even if the voters might have inadvertently thrown out the documents with the mayor.' Henyard initially made national headlines in April 2024 after officials in her administration were served with subpoenas from the FBI in response to an alleged corruption investigation, FOX 32 Chicago reported. Henyard, however, was never charged. In response to the FBI's investigation, village trustees voted to hire former Chicago Mayor Lori Lightful to investigate Henyard's spending during her time as mayor, with the meeting spiraling into chaos as Henyard's supporters clashed with her opponents. The financial probe reportedly revealed the village's bank account fell from its initial $5.6 million balance to a $3.6 million deficit. Earlier this year, Henyard subsequently lost the city's mayoral primary to Jason House, who was sworn into office in May. On the same day of her election loss, federal authorities slapped the Village of Dolton with a subpoena demanding records tied to a land development project allegedly tied to Henyard's boyfriend. Fox News Digital's Michael Dorgan contributed to this report.
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
